News
Company continues to progress both REYOBIQ radiotherapeutic clinical trials and CNSide® CSF assay platform launch readiness HOUSTON, May 30, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: ...
Russell Bradley as President and General Manager of Plus Therapeutics’ wholly owned subsidiary, CNSide Diagnostics, LLC (“CNSide Diagnostics”) - Mr. Bradley provides leadership to CNSide Diagnostics ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback